This invention describes a set of novel molecules that target and degrade DYRK/CLK for several potential therapeutic purposes. Background: Proteolysis-targeting chimeric molecules (PROTACs) are small molecules used to decrease a gene’s protein expression by targeting the protein for ubiquitination and degradation after it is created. This mechanism has applications in a range of therapeutics. One class of targets with therapeutic potential is the DYRK/CLK class of proteins. DYRK/CLK is associated with severity of COVID-19 infections, glioblastoma, and cognitive impairment such as Alzheimer’s Disease. In this technology, the inventors purpose a novel set of PROTACS molecules that target DYRK/CLK for ubiquitination and degradation for a range of potential therapeutic applications. The ligand that is tethered through a variety of linkers to an E3-ligase recruiter is novel relative to other PROTACs. Applications:
Advantages: